Nutriband Inc. (NASDAQ: NTRB), a company focused on transdermal pharmaceutical products, announced that 272,671 of its NTRBW warrants were exercised at a strike price of $6.43, generating approximately $1.75 million in gross proceeds. The warrants expired on September 30 without extension, leaving Nutriband with no remaining tradable warrants. This capital infusion is significant because it provides non-dilutive funding to support the remaining clinical development of AVERSA Fentanyl and the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval.
AVERSA Fentanyl is being developed as a potential first-of-its-kind opioid patch with abuse-deterrent properties. If approved, it could address a critical public health need by reducing the risk of abuse, misuse, diversion, and accidental exposure associated with transdermal fentanyl products. According to a 2022 Health Advances market analysis, AVERSA Fentanyl has estimated peak annual U.S. sales of $80 million to $200 million, underscoring its commercial potential. The proceeds from the warrant exercises are primarily allocated to advance this lead product, which incorporates Nutriband's proprietary AVERSA abuse-deterrent technology. This technology can be integrated into any transdermal patch to deter abuse of drugs with abuse potential.
The expiration of the warrants without extension simplifies Nutriband's capital structure and eliminates overhang from tradable warrants. The company now has a clearer path to focus on its core development activities. For investors, the successful warrant exercise demonstrates confidence in Nutriband's pipeline, as warrant holders chose to purchase shares at $6.43 rather than let them expire worthless. The funds raised are expected to cover the costs associated with the remaining clinical work and the regulatory submission process, which are critical milestones for any pharmaceutical company seeking FDA approval.
Nutriband's lead product, AVERSA Fentanyl, is part of a broader portfolio of transdermal pharmaceutical products under development. The company's AVERSA technology platform is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, making it a versatile solution for transdermal drug delivery. More information about Nutriband is available on its website at www.nutriband.com. The latest news and updates relating to NTRB can be found in the company's newsroom at https://ibn.fm/NTRB, and the full press release regarding the warrant exercises is accessible at https://ibn.fm/ZUBic.
The announcement was distributed through MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is part of the Dynamic Brand Portfolio at IBN, which offers a range of services including wire distribution via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit MissionIR or www.MissionIR.com. The terms of use and disclaimers are available at https://www.MissionIR.com/Disclaimer.
The ability to secure funding through warrant exercises reflects investor confidence in Nutriband's strategy and the potential of AVERSA Fentanyl. With no remaining tradable warrants, the company can now direct its full attention to advancing its pipeline and preparing for regulatory milestones. The successful development and approval of AVERSA Fentanyl could position Nutriband as a leader in abuse-deterrent transdermal therapies, addressing a significant unmet need in pain management and public health.
